biomea fusion inc - BMEA

BMEA

Close Chg Chg %
7.11 -0.17 -2.39%

Open Market

6.94

-0.17 (2.39%)

Volume: 137.23K

Last Updated:

Nov 15, 2024, 10:48 AM EDT

Company Overview: biomea fusion inc - BMEA

BMEA Key Data

Open

$7.02

Day Range

6.78 - 7.11

52 Week Range

3.61 - 22.74

Market Cap

$257.29M

Shares Outstanding

36.24M

Public Float

28.10M

Beta

-0.43

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$4.00

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

789.63K

 

BMEA Performance

1 Week
 
-13.08%
 
1 Month
 
-38.97%
 
3 Months
 
23.01%
 
1 Year
 
-31.63%
 
5 Years
 
N/A
 

BMEA Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 10
Full Ratings ➔

About biomea fusion inc - BMEA

Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. It offers its lead product candidate, BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in Redwood City, CA.

BMEA At a Glance

Biomea Fusion, Inc.
900 Middlefield Road
Redwood City, California 94063
Phone 1-650-980-9099 Revenue 0.00
Industry Pharmaceuticals: Major Net Income -117,255,000.00
Sector Health Technology Employees 103
Fiscal Year-end 12 / 2024
View SEC Filings

BMEA Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 3.077
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -2.695
Enterprise Value to Sales N/A
Total Debt to Enterprise Value 0.031

BMEA Efficiency

Revenue/Employee N/A
Income Per Employee -1,138,398.058
Receivables Turnover N/A
Total Asset Turnover N/A

BMEA Liquidity

Current Ratio 7.838
Quick Ratio 7.838
Cash Ratio 7.737

BMEA Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -71.114
Return on Equity -84.424
Return on Total Capital -65.311
Return on Invested Capital -81.633

BMEA Capital Structure

Total Debt to Total Equity 6.084
Total Debt to Total Capital 5.735
Total Debt to Total Assets 5.15
Long-Term Debt to Equity 4.627
Long-Term Debt to Total Capital 4.361
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Biomea Fusion Inc - BMEA

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
132.00K 953.00K 1.26M 4.20M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
132.00K 953.00K 1.26M 4.20M
Depreciation
132.00K 953.00K 1.26M 4.20M
Amortization of Intangibles
- - - -
-
COGS Growth
- +621.97% +32.42% +232.88%
Gross Income
(132.00K) (953.00K) (1.26M) (4.20M)
Gross Income Growth
- -621.97% -32.42% -232.88%
Gross Profit Margin
- - - -
-
2020 2021 2022 2023 5-year trend
SG&A Expense
5.20M 40.71M 82.37M 121.93M
Research & Development
3.67M 28.00M 62.71M 102.55M
Other SG&A
1.52M 12.72M 19.66M 19.39M
SGA Growth
+334.73% +683.72% +102.32% +48.03%
Other Operating Expense
- - - -
-
Unusual Expense
- - - -
-
EBIT after Unusual Expense
(5.33M) (41.67M) (83.63M) (126.14M)
Non Operating Income/Expense
3.00K 100.00K 1.81M 8.88M
Non-Operating Interest Income
- - - 100.00K
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(5.32M) (41.57M) (81.83M) (117.25M)
Pretax Income Growth
-344.41% -680.75% -96.86% -43.29%
Pretax Margin
- - - -
-
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(5.32M) (41.57M) (81.83M) (117.25M)
Minority Interest Expense
- - - -
-
Net Income
(5.32M) (41.57M) (81.83M) (117.25M)
Net Income Growth
-344.41% -680.75% -96.86% -43.29%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(5.32M) (41.57M) (81.83M) (117.25M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(5.32M) (41.57M) (81.83M) (117.25M)
EPS (Basic)
-0.1768 -1.4277 -2.7955 -3.4379
EPS (Basic) Growth
-344.22% -707.52% -95.80% -22.98%
Basic Shares Outstanding
30.12M 29.12M 29.27M 34.11M
EPS (Diluted)
-0.1768 -1.4277 -2.7955 -3.4379
EPS (Diluted) Growth
-344.22% -707.52% -95.80% -22.98%
Diluted Shares Outstanding
30.12M 29.12M 29.27M 34.11M
EBITDA
(5.20M) (40.71M) (82.37M) (121.93M)
EBITDA Growth
-334.73% -683.72% -102.32% -48.03%
EBITDA Margin
- - - -
-

Snapshot

Average Recommendation BUY Average Target Price 40.40
Number of Ratings 10 Current Quarters Estimate -0.916
FY Report Date 12 / 2024 Current Year's Estimate -3.901
Last Quarter’s Earnings -0.91 Median PE on CY Estimate N/A
Year Ago Earnings -3.44 Next Fiscal Year Estimate -3.584
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 10 4 10 10
Mean Estimate -0.92 -0.81 -3.90 -3.58
High Estimates -0.77 -0.23 -3.48 -0.89
Low Estimate -1.20 -1.15 -4.23 -5.29
Coefficient of Variance -13.96 -52.03 -5.03 -34.51

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 8 8 5
OVERWEIGHT 0 0 1
HOLD 2 2 4
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Overweight

Insider Actions for Biomea Fusion Inc - BMEA

Date Name Shares Transaction Value
Jun 14, 2024 Sumita Ray Director 51,025 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 14, 2024 Bihua Chen Director 51 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 14, 2024 Eric I. Aguiar Director 51,025 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 14, 2024 Elizabeth A. Faust Director 51,025 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 14, 2024 Michael J. M. Hitchcock Director 51,025 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 13, 2024 Juan Pablo Frias Chief Medical Officer 349 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $8.94 per share 3,120.06

Biomea Fusion Inc in the News